UK FMD (foot and mouth disease) animal restrictions lifted but tissue technology industry awaits:
This article was originally published in Clinica
Executive Summary
At the time of going to press, Clinica was awaiting confirmation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regarding possible changes to restrictions imposed on the trade of medical devices containing material sourced from biungulate animals, in light of the outbreaks of foot and mouth disease (FMD) in southern England earlier this month. Despite the early lifting of some restrictions on the movement and international trade of animals and products, an agency spokesperson could not confirm, on the eve of going to press, whether there had been any change to the situation, as set out in its August 14 notice (see Clinica No 1269, p 5).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.